双特异双免疫检查点抑制剂相关的皮肤毒性:两名癌症患者的Lorigerlimab不良皮肤反应报告
Niloofar Sina1, Fiorinda Muhaj2, Volha Lenskaya3
1Department of Pathology, Section of Dermatopathology, University Health Network, University of Toronto, Toronto, Ontario, Canada.
洛里格利马布是一种双双特异性抗体,可以引起皮肤免疫相关不良事件 (irAEs). 组织病理学评估对于在晚期癌症患者中管理这些皮肤毒性至关重要.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
背景情况:
- 洛里格利马布是一种双双特异性抗体 (BsAb),针对高级固体癌症的CTLA-4和PD-1.
- 报道了皮肤免疫相关的不良事件 (irAEs),如和皮疹,但在组织病理上没有很好的特征.
- 使用BSAbs的双重免疫检查点封锁在管理皮肤毒性方面提出了独特的挑战.
研究的目的:
- 描述与lorigerlimab相关的皮肤irrAEs的临床和本病学特征.
- 为了研究洛里格利马布诱导的皮肤炎的治疗反应.
- 强调组织病理学在指导这些IRAE的管理中的重要性.
主要方法:
- 两名患有转移性割抵抗性前列腺腺癌的患者的病例报告,他们接受了lorigerlimab治疗.
- 皮肤喷发的详细临床描述.
- 皮肤活检的组织病理学分析.
主要成果:
- 患者1:发病了紫色的,斑块性喷发与状体,周血管性皮肤炎,对皮质类固醇和药物禁用有反应.
- 患者2:呈现出严重的,混合的牛皮形,湿疹和形皮疹,带有真空界面变化和acantholysis,不耐治疗.
- 第二名患者的irAE导致完全停止使用lorigerlimab.
结论:
- 洛里格利马布可以诱导不同的皮肤iRAE模式,包括状和真空界面皮肤炎.
- 组织病理学检查对于准确的诊断和指导洛里格利马布相关皮肤毒性的治疗策略至关重要.
- 需要进一步的研究,以充分理解和管理双重免疫检查点抑制剂 (如lorigerlimab.
更多相关视频
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
08:01Cutaneous Surgical Denervation: A Method for Testing the Requirement for Nerves in Mouse Models of Skin Disease
Published on: June 26, 2016
相关概念视频
11:35Dual-mode Imaging of Cutaneous Tissue Oxygenation and Vascular Function
10:18Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
08:01Cutaneous Surgical Denervation: A Method for Testing the Requirement for Nerves in Mouse Models of Skin Disease
04:23Frozen Skin Tissue Block Preparation: A Protocol to Preserve Cutaneous Melanoma Samples from Murine Dorsal Skin
Toxic Reactions: Overview
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
09:53Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies
